Literature DB >> 30900256

Insurance status, stage of presentation, and survival among female patients with head and neck cancer.

Neelima Panth1, Matthew C Simpson2, Rosh K V Sethi3, Mark A Varvares3, Nosayaba Osazuwa-Peters2,4.   

Abstract

OBJECTIVES: Incidence trends and outcomes of head and neck cancer (HNC) among female patients are not well understood. The objective of this study was to estimate incidence trends and quantify the association between health insurance status, stage at presentation, and survival among females with HNC. STUDY
DESIGN: Retrospective cohort study.
METHODS: The Surveillance, Epidemiology, and End Results database (2007-2014) was queried for females aged ≥18 years diagnosed with a malignant primary head and neck cancer (HNC) (n = 18,923). Incidence trends for stage at presentation were estimated using Joinpoint regression analysis. The association between health insurance status and stage at presentation on overall and disease-specific survival was estimated using Fine and Gray proportional hazards models.
RESULTS: Incidence of stage IV HNC rose by 1.24% from 2007 to 2014 (annual percent change = 1.24, 95% CI 0.30, 2.20). Patients with Medicaid (adjusted odds ratio [aOR] = 1.59, 95% confidence interval [CI] 1.45, 1.74) and who were uninsured (aOR = 1.73, 95% CI 1.47, 2.04) were more likely to be diagnosed with advanced stage (stages III/IV) HNC. Similarly, patients with Medicaid (adjusted hazard ratio [aHR] = 1.47, 95% CI 1.38, 1.56) and who were uninsured (aHR =1.45, 95% CI 1.29, 1.63) were more likely to die from any cause compared to privately insured patients. Medicaid (aHR = 1.34, 95% CI 1.24, 1.44) and uninsured (aHR = 1.41, 95% CI 1.24, 1.60) patients also had a greater hazard of HNC-specific deaths compared to privately insured patients.
CONCLUSIONS: Incidence of advanced-stage presentation for female HNC patients in the United States has increased significantly since 2007, and patients who are uninsured or enrolled in Medicaid are more likely to present with late stage disease and die earlier. LEVEL OF EVIDENCE: NA Laryngoscope, 130:385-391, 2020.
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Head and neck cancer (HNC); SEER; cancer survivorship; cancer-specific survival; health insurance status; overall survival; stage of presentation

Year:  2019        PMID: 30900256     DOI: 10.1002/lary.27929

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  Mono-institutional retrospective cohort analysis of the insurance status dependent access to ENT-professionals and survival in head and neck squamous cell carcinoma.

Authors:  Andreas Knopf; Simon Teutsch; Henning Bier
Journal:  BMC Health Serv Res       Date:  2021-01-08       Impact factor: 2.655

2.  Evaluation of Patient-Reported Delays and Affordability-Related Barriers to Care in Head and Neck Cancer.

Authors:  Nicholas R Lenze; Jeannette T Bensen; Laura Farnan; Siddharth Sheth; Jose P Zevallos; Wendell G Yarbrough; Adam M Zanation
Journal:  OTO Open       Date:  2021-12-12

Review 3.  An equity-based narrative review of barriers to timely postoperative radiation therapy for patients with head and neck squamous cell carcinoma.

Authors:  Elizabeth A Noyes; Ciersten A Burks; Andrew R Larson; Daniel G Deschler
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-11-09

4.  Socioeconomic influence on treatment and outcome of patients with oral cancer in Germany.

Authors:  Christoph Klingelhöffer; Annegret Obst; Johannes K Meier; Torsten E Reichert; Tobias Ettl; Steffen Mueller
Journal:  Oral Maxillofac Surg       Date:  2021-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.